Drug Database
Back to search

Netherlands· NL-d7984d540757

Mylotarg 5 mg, poeder voor concentraat voor oplossing voor infusie

A gemtuzumab ozogamicin product containing gemtuzumab ozogamicine, registered in Netherlands by Pfizer Europe MA EEIG. The same ATC class is registered in 12 of our 19 countries.

ATC L01FX02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedMylotarg 5 mg, poeder voor concentraa…ATCL01FX02REGISTER NO.NL-d7984d540757PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about gemtuzumab ozogamicineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Gemtuzumab ozogamicin is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FX02 (gemtuzumab ozogamicin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search gemtuzumab ozogamicin products by name

Gemtuzumab ozogamicin · ATC L01FX02

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
GEMTUZUMAB OZOGAMICINE
Manufacturer
Pfizer Europe MA EEIG
Country
Netherlands (NL)
ATC code
L01FX02
ATC class
Gemtuzumab ozogamicin
Defined daily dose
2.1 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/18/1277

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

112 interactions on record for gemtuzumab ozogamicin.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check gemtuzumab ozogamicin against other medicinesHow interaction checks work

Gemtuzumab ozogamicin · interactions on record

112 records

  • 33 severe
  • 64 moderate
  • 15 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CladribineL01BB04severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gemtuzumab ozogamicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gemtuzumab ozogamicin products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Mylotarg
  • Liechtenstein · Mylotarg
  • Norway · Mylotarg

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/04051b44-c676-4353-ad10-9fc9a1ca882d
GET /v1/drugs/04051b44-c676-4353-ad10-9fc9a1ca882d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Gemtuzumab ozogamicin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp120395",
  "excipients": [
    "DEXTRAAN 40",
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "SACCHAROSE"
  ],
  "substances": [
    "GEMTUZUMAB OZOGAMICINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/04/19",
  "procedure_number": "EMEA/H/C/004204",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1277",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about gemtuzumab ozogamicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console